Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nuheara (NUH) receives ethics approval from the Australian Hearing Human Research Ethics Committee (AHHREC) to kick off its medical device clinical trial
  • This follows the company’s recent engagement with National Acoustics Laboratories to conduct a clinical trial to test the safety and effectiveness of Nuheara’s newly developed range of hearing products
  • Recruitment has already begun for the trial, which the company says supports its planned expansion into clinically tested and regulatory approved medical devices
  • Nuheara shares are down 3.33 per cent, trading at 2.9 cents at 11:20 am AEST

Nuheara (NUH) has received ethics approval from the Australian Hearing Human Research Ethics Committee (AHHREC) to commence its medical device clinical trial.

Nuheara has been working to develop multi-functional, personalised, intelligent hearing devices that augment a person’s hearing.  

This follows the company’s recent announcement that it engaged with the National Acoustics Laboratories to conduct a clinical trial to test the safety and effectiveness of Nuheara’s newly developed range of hearing products.

The company said this supports its planned expansion into clinically tested and regulatory approved medical devices.

Nuheara Co-founder, Managing Director and CEO Justin Miller said National Acoustics Laboratories has now commenced recruiting for Nuheara’s medical device clinical trial.

“We look forward to receiving the results of this trial, which we believe will support Nuheara in expanding its global hearing solutions by meeting hearing aid compliance requirements initially with the U.S. Food and Drug Administration, the European Union and the Australian Therapeutic Goods Administration.”

“Receiving regulatory approval will open substantial new market opportunities for Nuheara in the US, Europe and Australia.”

Nuheara shares were down 3.33 per cent, trading at 2.9 cents at 11:20 am AEST.

NUH by the numbers
More From The Market Herald

" Appen (ASX:APX) positioned to weather pandemic, reaffirms guidance

Data annotation and artificial intelligence company Appen (ASX:APX) has today reaffirmed its guidance for the 2020…

" Appen (ASX:APX) sailing through COVID-19 storm unaffected

Appen (ASX:APX) has reaffirmed its yearly financial guidance and expects only a negligible impact from the…

" Appen (ASX:APX) downgrades earnings guidance as growth stutters

Machine learning and AI specialist Appen (ASX:APX) has downgraded its 2020 earnings guidance due to the…

" MSL Solutions (ASX:MSL) wins Stadiums Queensland contract

Sports, leisure and hospitality SaaS technology provider MSL Solutions (ASX:MSL) has signed a five-year contract with…